



## Genocea to Present at BIO Investor Forum

Cambridge, MA, Oct. 24, 2011 (BUSINESSWIRE) – Genocea Biosciences, Inc. today announced that the company's President and Chief Executive Officer, Chip Clark, will provide an overview of the company's technology and development programs at the BIO Investor Forum (San Francisco, October 26; presentation at 9:00 p.m. PST).

### About Genocea

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Pneumococcus, and *Chlamydia trachomatis*, infections that affect hundreds of millions of people worldwide.

CONTACT: Chip Clark, President and CEO, Genocea Biosciences +1.617.876.8191